Detecting agent and therapeutic agent for highly malignant...

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S007100, C436S501000, C436S518000

Reexamination Certificate

active

08030014

ABSTRACT:
A detection agent for high malignancy breast cancer includes an antibody against collagen XIV, or a variant or derivative or fragment of the antibody. A therapeutic agent for high malignancy breast cancer includes a conjugate of an anticancer drug and an antibody against that protein, or a variant or derivative or fragment thereof. Accordingly, it is possible to easily and accurately detect and diagnose high malignancy breast cancer.

REFERENCES:
patent: 5185450 (1993-02-01), Owen
patent: 63500245 (1988-01-01), None
patent: 2004151003 (2004-05-01), None
patent: 2004097030 (2004-11-01), None
Klein et al Matrix Biol. 16:307-317, 1997.
Berthod et al, J Invest Dermatol.108:737-742, 1997.
Atherton et al, Cell Tissue Res 291: 507-511, 1998.
Atherton, Amanda J. et al., “Differential expression of type XIV collagen/undulin by human mammary gland intralobular and interlobular fibroblasts”, Cell and Tissue Research, vol. 291, No. 3, Mar. 1998, pp. 507-511.
Klein Gerd et al., “Cell Binding Properties of Collagen Type XIV for Human Hematopoietic Cells”, Matrix Biology, vol. 16, No. 6, 1997/98, pp. 307-317.
Ehnis, Tobias et al., “Localization of a Binding Site for the Proteoglycan Decorin on Collagen XIV (Undulin)”, The Journal of Biological Chemistry, vol. 272, No. 33, Aug. 15, 1997, pp. 20414-20419.
Tono-Oka, Shiro et al., “Transient Expression of Collagen Type XIV During Muscle Development and Its Reappearance After Denervation and Degeneration”, The Journal of Histochemistry and Cytochemistry, vol. 44, No. 8, 1996, pp. 907-918.
Woelfle et al., “Molecular Signature Associated with Bone Marrow Micrometastasis in Human Breast Cancer”, Cancer Res., vol. 63, pp. 5679-5684, Sep. 15, 2003.
Jacquemier et al., “Protein Expression Profiling Identifies Subclasses of Breast Cancer and Predicts Prognosis”, Cancer Res., vol. 65, pp. 767-779, Feb. 1, 2005.
Lim et al., “Proteomics in Pathology Research”, Lab Invest., vol. 84, pp. 1227-1244, Aug. 16, 2004.
Adam et al., “Comprehensive Proteomic Analysis of Breast Cancer Cell Membranes Reveals Unique Proteins with Potential Roles in Clinical Cancer”, J. Biol. Chem., vol. 278, No. 8, pp. 6482-6489, Feb. 21, 2003.
Jessani et al., “Enzyme Activity Profiles of the Secreted and Membrane Proteome that Depict Cancer Cell Invasiveness”, Proc. Natl. Acad. Sci. USA, vol. 99, No. 16, pp. 10335-10340, Aug. 6, 2002.
Schuppan et al., “Undulin, an Extracellular Matrix Glycoprotein Associated with Collagen Fibrils”, J. Biol. Chem., vol. 265, No. 15, pp. 8823-8832, May 25, 1990.
Just et al., “Undulin is a Novel Member of the Fibronectin-Tenascin Family of Extracellular Matrix Glycoproteins”, J. Biol. Chem., vol. 266, No. 26, pp. 17326-17332, Sep. 15, 1991.
Atherton et al., “Differential Expression of Type XIV Collagen/Undulin by Human Mammary Gland Intralobular and Intralobular Fibroblasts”, Cell Tissue Res., vol. 291, pp. 507-511, 1998.
Ehnis et al., “A Chondroitin/Dermatan Sulfate Form of CD44 Is a Receptor for Collagen XIV (Undulin)”, Exp. Cell Res., vol. 229, pp. 388-397, 1996.
Ennis et al., “Localization of a Binding Site for the Proteoglycan Decorin on Collagen XIV (Undulin)”, J. Biol. Chem., vol. 272, No. 33, pp. 20414-20419, Aug. 15, 1997.
Paulus et al., “Characterization of Integrin Receptors in Normal and Neoplastic Human Brain”, Am. J. Pathol., vol. 143, No. 1, pp. 154-163, Jul. 1993.
Ruehl et al., “The Elongated First Fibronectin Type III Domain of Collagen XIV is an Inducer of Quiescence and Differentiation in Fibroblasts and Preadipocytes”, J. Biol. Chem., vol. 280, No. 46, pp. 38537-38543, Nov. 18, 2005.
Gerecke et al., “Type XIV Collagen is Encoded by Alternative Transcripts with Distinct 5′ Regions and is a Multidomain Protein with Homologies to von Willebrand's Factor, Fibronectin, and Other Matrix Proteins”, J. Biol. Chem., vol. 268, No. 16, pp. 12177-12184, Jun. 5, 1993.
Pawitan et al., “Gene Expression Profiling Spares Early Breast Cancer Patients From Adjuvant Therapy: Derived and Validated in Two Population-Based Cohorts”, Breast Cancer Research, vol. 7, No. 6, pp. 953-964, 2005, with Supplementary Report dated Aug. 18, 2005.
“New Drug Delivery System”, First Edition, CMC Publishing Co., Ltd., Tokyo, pp. 165-167, Jan. 31, 2000.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Detecting agent and therapeutic agent for highly malignant... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Detecting agent and therapeutic agent for highly malignant..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detecting agent and therapeutic agent for highly malignant... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4284855

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.